Peptide Straight Talk · Free beginner reference · Educational only · Not medical advice
Revision date: September 20, 2026
Beginner Glossary & Evidence Cheat Sheet
Peptide Straight Talk labels claims so you can see what kind of study is being discussed and what source you are actually reading. Labels identify sources; they do not establish truth.
We spell out each abbreviation when it first appears in an issue, then use the short form. For example: randomized controlled trial (RCT).
No dosing, no protocols, no calculator, no “how to take” guidance.
1. What is a peptide?
Peptide — A short chain of amino acids (the building blocks of proteins). Many medicines and research compounds are peptides or peptide-related; the word alone does not tell you whether something is approved, safe, or effective.
2. Basic vocabulary (starter set)
Term | Plain English |
|---|---|
Investigational | Still being studied; not an approved marketed use. |
Compounding | Preparing a customized medicine under applicable compounding rules. See the detailed 503A explanation below. |
Identity | Confirming the molecule named on a label or claim matches the molecule discussed in a citation. |
Evidence ceiling | The strongest honest label level for a claim right now, given the sources available. |
Topline | High-level summary results (often from a company/sponsor) before a full research paper is available. |
Primary endpoint | The main outcome a trial was designed to measure. |
3. Evidence & source labels — two questions
When you see a claim, ask two separate questions. Study design is not the same as publication status.
Question | Example labels (chip codes) |
|---|---|
What kind of study? | Randomized trial (RCT), Nonrandomized human (NR-H), Animal (ANIMAL), Laboratory / in vitro (IVT), Case report / series (CR/CS), Review / synthesis (REV) |
What source are we reading? | Journal article (including original study results: JOURNAL-PRIMARY), Conference materials (CONF), Company / sponsor release (SPONSOR), Registry record (REG), Regulatory / authority statement (REG-AUTH), Community / vendor / internet (COMM) |
Teaching example: “Randomized trial · Company announcement · Full report not yet available.”
That line can be accurate: an RCT is a study design (random assignment). A company announcement or conference talk can report an RCT without being a full journal paper.
NCI-style idea: A randomized controlled trial is a study in which participants are randomly assigned to groups that receive different interventions (or placebo/control). Randomization is about assignment design, not about whether results have been peer-reviewed or published. See NCI Dictionary — randomized controlled trial.
Axis A — What kind of study?
RCT — randomized controlled trial (study design)
A human study in which participants are randomly assigned to different groups (for example, treatment vs. comparison). Randomization helps reduce bias in how people end up in each group. Study quality, size, relevance, and how carefully results are reported still need assessment.
Means:
The design used random assignment (when that is accurately described)
Human experimental evidence that, when fully reported, is often easier to interpret than nonrandomized comparisons — if methods and outcomes are available to evaluate
Does not mean:
“Safe for everyone”
“FDA-approved”
“You should use this”
That a registry status of COMPLETED proves the treatment worked
That every press release or conference slide deck is a full research paper (those are sources; they may describe an RCT)
Important: A conference presentation (CONF) or company announcement (SPONSOR) can report an RCT. That does not turn the announcement into a full journal report. Design and source stay on separate axes.
NR-H — nonrandomized human study (study design)
A human study with results you can examine in which participants were not randomly assigned (or randomization is not the design used).
Means:
Real human data
Design control is weaker than a well-run randomized trial for separating treatment effects from other differences between groups
Does not mean:
Equivalent to RCT
Proof of broad safety or efficacy
ANIMAL — in vivo animal study (study design)
Research done in living animals (mice, rats, and so on).
Means:
Useful for biology and early signals
Does not mean:
The same result is proven in people
A human dose or protocol
IVT — in vitro / cell / tissue / lab assay (study design)
Experiments in cells, tissues, or test tubes — not in a whole living person.
Means:
Mechanism clues and early lab signals
Does not mean:
A human treatment effect
Something you can buy and “run” as a protocol
CR/CS — case report / case series (study design)
A case report describes one patient’s experience. A case series describes a group of patients with a similar condition or exposure, typically without a concurrent control group. What defines a series is the design (descriptive group report), not a small sample size — N can be few or many.
Means:
Interesting clinical observation or anecdote
Does not mean:
Population-level proof
That two patients equal a safety program
REV — review / synthesis (study design / secondary)
A secondary paper that summarizes other studies (narrative review, systematic review, and similar).
Means:
A map of the literature — quality depends on what it cites
Does not mean:
New primary trial results by itself
Automatic upgrade of weak primary sources
Axis B — What source are we reading?
Journal article (full report)
A full research paper (often peer-reviewed) with methods, results, and discussion you can read end-to-end.
Means:
You can usually check tables, methods, and outcomes in one place
Does not mean:
Automatic proof that findings apply to every reader
That quality is always high (papers still need careful reading)
JOURNAL-PRIMARY — a journal article reporting original study results.
Peer-review status is recorded separately as confirmed, absent, unknown, or not applicable. Journal publication alone does not establish peer review, study quality, safety, or efficacy.
CONF — conference presentation / abstract / symposium materials (source)
Results shown at a scientific meeting (talk, poster, slides, abstract). Public and useful — but not the same as a finished full journal paper.
Means:
“Presented in public at a meeting”
May describe a randomized trial or other study design — check the design label separately
Does not mean:
A full peer-reviewed primary publication by itself
That numbers on slides are final forever
SPONSOR — company topline / investor press release (source)
The drug company (or sponsor) announced results in a news release or investor note.
Means:
“The company says…” — news or investor communication, not a journal paper
May describe a randomized trial or other study — keep design and source separate
Does not mean:
Peer-reviewed primary tables
FDA approval
That the announcement is the full research report
REG — trial registry record (source)
An entry on a public trial registry (often ClinicalTrials.gov) describing a study’s plan, status, dates, and population. Some registry records also post results / outcome tables when the sponsor or investigators upload them.
Means:
You can verify registration and check design and status fields (for example, Recruiting, Completed)
When posted registry results are present, you can review those outcome tables as registry-hosted data — still a registry source, not automatically a full journal paper
Does not mean:
That a status of Completed means results are published — or that the treatment worked
That every registry page includes outcome tables (many do not)
That registry results equal a peer-reviewed full report
Teaching line: Completed does not mean results are published — or that the treatment worked.
An official position from a regulator or similar authority (example: U.S. Food and Drug Administration (FDA) pages about compounding, approval status, or safety concerns).
Means:
“Here’s what the agency/authority currently says”
Does not mean:
A personal recommendation
That harm is always “proven” (sometimes the language is uncertainty — we keep that wording)
That research-chem marketplace vials are approved drugs
COMM — community / vendor / internet claim (source)
Forum posts, catalog aliases, influencer “stacks,” unsourced marketing copy.
Means:
A commercial claim or community claim; check its supporting sources
Does not mean:
Established evidence
Dosing advice (we never treat COMM as dosing guidance)
That a vial alias equals pharmaceutical trial material
Upcoming event / watch status
WATCH-NEXT marks an upcoming event, not a source type. Identify the actual source of the announcement, such as a conference agenda or company announcement. A scheduled presentation does not establish results.
Something is scheduled to be presented or released later (example: a conference agenda listing).
Means:
“Put it on the calendar”
A scheduled presentation alone does not establish results
Does not mean:
New peer-reviewed results today
Permission to treat a title or time slot as published data
Quick trap table
Trap people fall into | Clearer reading |
|---|---|
ClinicalTrials.gov says COMPLETED | Status field only unless posted registry results are also there; still a REG source. Completed does not mean results are published — or that the treatment worked. |
Company press release with big % | SPONSOR source — may describe an RCT design, but it is not a full journal report |
Just presented at a meeting | CONF source — may describe an RCT; not automatically a full paper |
FDA mentioned the compound | Read the REG-AUTH text carefully — often “not approved,” compounding limits, or limited safety information |
Vendor protocol chart | COMM — a commercial claim; check its supporting sources |
4. Common abbreviations
Abbrev. | Spelled out | Short meaning |
|---|---|---|
FDA | U.S. Food and Drug Administration | Principal U.S. regulator for drugs, devices, biologics, and foods |
PMID | PubMed Identifier | ID number for a paper indexed in PubMed |
DOI | Digital Object Identifier | Persistent identifier for a paper or digital object (looks like 10.…) |
NCT | ClinicalTrials.gov identifier (NCT number) | Study ID on ClinicalTrials.gov (starts with NCT…) — not “National Clinical Trial number” |
INN | International Nonproprietary Name | A globally recognized generic name identifying a pharmaceutical substance. WHO publishes proposed names for comment before a separate recommended-name stage. Retatrutide appears in Proposed INN List 128 (WHO Drug Information 36(4), 2022, page 1051; posted January 19, 2023). That historical entry records the proposed stage; it does not establish current naming status, drug approval, or a recommendation for medical use. |
PCAC | Pharmacy Compounding Advisory Committee | FDA advisory committee on certain compounding topics; recommendations are not final FDA rules by themselves |
503A | Section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act) | Traditional compounding by a licensed pharmacist or eligible licensed physician, typically for an identified patient under a valid prescription / conditional order. Bulk substances follow FDA’s conditional sequence: (1) applicable USP/NF monograph + applicable compounding chapter; (2) if no applicable monograph, component of an FDA-approved drug; (3) if neither, must appear on the 503A Bulks List |
Bulks List | 503A Bulks List (informal name) | The third step in FDA’s 503A bulk pathway (after the monograph and approved-drug-component routes). FDA distinguishes substances on the list from nominations, interim categories, and substances evaluated but not included — those are not the same thing |
BLA | Biologics License Application | Formal application asking FDA to license a biologic |
AE | Adverse event | Unwanted medical occurrence in a study (not always proven caused by the drug) |
GI | Gastrointestinal | Stomach / intestines-related |
PK / PD | Pharmacokinetics / Pharmacodynamics | How the body handles a drug / what the drug does to the body |
SC | Subcutaneous | Under the skin (route described in studies — not instructions) |
IV | Intravenous | Into a vein (route described in studies — not instructions) |
COA | Certificate of Analysis | Lab report on a batch’s tested attributes — not proof of clinical benefit |
GLP-1 / GIP | Glucagon-like peptide-1 / Glucose-dependent insulinotropic polypeptide | Gut hormone pathways targeted by some metabolic drugs |
α-MSH | Alpha-melanocyte-stimulating hormone | A natural peptide; some research peptides are related fragments or analogs |
T2D | Type 2 diabetes | A metabolic disease label used in many trial populations |
BMI | Body mass index | Weight/height index used in obesity research eligibility |
ADA | American Diabetes Association | Health / professional organization (scientific meetings and related materials; context-dependent) |
EASD | European Association for the Study of Diabetes | Scientific society / meetings |
NEJM | New England Journal of Medicine | Major peer-reviewed medical journal |
USP/NF | United States Pharmacopeia / National Formulary | Official quality standards for many drug substances and products |
What this cheat sheet is not
Not medical advice
Not a dosing or reconstitution guide
Not permission for unapproved human use
Not a shopping list
Not a substitute for reading primary sources
Sources
Study labels: RCT, NR-H, ANIMAL, IVT, CR/CS, REV. Source labels: journal article (including JOURNAL-PRIMARY for original study results), CONF, SPONSOR, REG, REG-AUTH, COMM. WATCH-NEXT is a separate upcoming-event status. Keep study design, source type, and publication or peer-review status distinct.
© 2026 Peptide Straight Talk · Educational research intelligence · Free beginner reference
Revision date: September 20, 2026